ANI Pharmaceuticals Inc
NASDAQ:ANIP
Intrinsic Value
ANI Pharmaceuticals, Inc. is a pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. [ Read More ]
The intrinsic value of one ANIP stock under the Base Case scenario is 85.07 USD. Compared to the current market price of 65.48 USD, ANI Pharmaceuticals Inc is Undervalued by 23%.
Valuation Backtest
ANI Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling ANIP stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
ANI Pharmaceuticals Inc
Current Assets | 519.8m |
Cash & Short-Term Investments | 221.1m |
Receivables | 162.1m |
Other Current Assets | 136.6m |
Non-Current Assets | 384.6m |
PP&E | 44.6m |
Intangibles | 237.2m |
Other Non-Current Assets | 102.8m |
Current Liabilities | 145.5m |
Accounts Payable | 36.7m |
Accrued Liabilities | 57.8m |
Other Current Liabilities | 51m |
Non-Current Liabilities | 301.3m |
Long-Term Debt | 284.8m |
Other Non-Current Liabilities | 16.5m |
Earnings Waterfall
ANI Pharmaceuticals Inc
Revenue
|
486.8m
USD
|
Cost of Revenue
|
-181.5m
USD
|
Gross Profit
|
305.3m
USD
|
Operating Expenses
|
-257.2m
USD
|
Operating Income
|
48.1m
USD
|
Other Expenses
|
-32.6m
USD
|
Net Income
|
15.5m
USD
|
Free Cash Flow Analysis
ANI Pharmaceuticals Inc
What is Free Cash Flow?
ANIP Profitability Score
Profitability Due Diligence
ANI Pharmaceuticals Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
Score
ANI Pharmaceuticals Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
ANIP Solvency Score
Solvency Due Diligence
ANI Pharmaceuticals Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
ANI Pharmaceuticals Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ANIP Price Targets Summary
ANI Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for ANIP is 81.4 USD with a low forecast of 77.77 USD and a high forecast of 87.15 USD.
Ownership
ANIP Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ANIP Price
ANI Pharmaceuticals Inc
Average Annual Return | -5.36% |
Standard Deviation of Annual Returns | 44.28% |
Max Drawdown | -73% |
Market Capitalization | 1.3B USD |
Shares Outstanding | 21 080 000 |
Percentage of Shares Shorted | 1.22% |
ANIP News
Last Important Events
ANI Pharmaceuticals Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
ANI Pharmaceuticals Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
ANI Pharmaceuticals, Inc. is a pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The company is headquartered in Baudette, Minnesota and currently employs 601 full-time employees. The company went IPO on 2000-05-04. The firm is focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The firm focuses on areas, including controlled substances, oncology products (anti-cancer), hormones and steroids, and complex formulations. The Company’s products include both branded and generic pharmaceuticals. Its generic products include Aspirin and Extended Release Dipyridamole, Bretylium Tosylate Injection USP, cholestyramine, Etodolac, Fluvoxamine, Indapamide, Nilutamide, Vancomycin and more. Its branded products include Arimidex (anastrozole) tablets, Atacand HCT Tablets, Atacand (candesartan cilexetil) Tablets, Casodex, Cortenema, Cortrophin gel, Cortrophin-Zinc, Inderal LA, Inderal XL, InnoPran XL, Lithobid, Reglan and Vancocin. The company operates across three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota and one is located in Oakville, Ontario.
Contact
IPO
Employees
Officers
The intrinsic value of one ANIP stock under the Base Case scenario is 85.07 USD.
Compared to the current market price of 65.48 USD, ANI Pharmaceuticals Inc is Undervalued by 23%.